Holen Sie sich die Stockscreener-App
2.32
6.07%
-0.15
Handel nachbörslich:
2.28
-0.04
-1.72%
Schlusskurs vom Vortag:
$2.47
Offen:
$2.54
24-Stunden-Volumen:
1.01M
Relative Volume:
0.56
Marktkapitalisierung:
$165.34M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-292.19M
KGV:
-0.511
EPS:
-4.54
Netto-Cashflow:
$-208.41M
1W Leistung:
-4.53%
1M Leistung:
+3.11%
6M Leistung:
-29.70%
1J Leistung:
-83.02%
1-Tages-Spanne:
$2.185
$2.59
1-Wochen-Bereich:
$2.185
$2.635
52-Wochen-Spanne:
$1.61
$18.07
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Firmenname
Zentalis Pharmaceuticals Inc
Sektor
Branche
Telefon
(858) 263-4333
Adresse
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Vergleichen Sie ZNTL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
2.32 | 165.34M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-12 | Hochstufung | Wedbush | Underperform → Neutral |
| 2024-06-20 | Herabstufung | UBS | Buy → Neutral |
| 2024-06-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-06-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | Herabstufung | Wedbush | Neutral → Underperform |
| 2024-06-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-11-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | Eingeleitet | Cowen | Outperform |
| 2022-04-06 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-29 | Eingeleitet | Oppenheimer | Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-01-20 | Eingeleitet | Wedbush | Outperform |
| 2020-09-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-08-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-28 | Eingeleitet | Guggenheim | Buy |
| 2020-04-28 | Eingeleitet | Jefferies | Buy |
| 2020-04-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Zentalis Pharmaceuticals Inc Aktie (ZNTL) Neueste Nachrichten
Zentalis Pharmaceuticals (ZNTL): Among Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
Savant Capital LLC Acquires New Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc.ZNTL - PR Newswire
Zentalis stock plunges to 52-week low, hits $2.16 - MSN
Zentalis Pharmaceuticals' chief medical officer acquires $45,656 in stock - MSN
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $8.24 Consensus PT from Brokerages - MarketBeat
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Insider Ingmar Bruns Buys 20,000 Shares - MarketBeat
What is Leerink Partnrs' Forecast for ZNTL Q3 Earnings? - MarketBeat
Zentalis Pharmaceuticals' chief medical officer acquires $45,656 in stock By Investing.com - Investing.com Australia
Chief Medical Officer Bruns Ingmar bought $45,656 worth of shares (20,000 units at $2.28), increasing direct ownership by 120% to 36,629 units (SEC Form 4) - Quantisnow
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of “Hold” by Analysts - Defense World
Q1 Earnings Estimate for ZNTL Issued By Leerink Partnrs - MarketBeat
What is Leerink Partnrs’ Estimate for ZNTL Q3 Earnings? - Defense World
Zentalis Pharmaceuticals executive sells shares worth $4,475 - MSN
Potential Price Increase for Zentalis Pharmaceuticals Inc (ZNTL) After Recent Insider Activity - Knox Daily
SG Americas Securities LLC Buys 30,240 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals Inc’s (ZNTL) Stock: A Week-by-Week Analysis - The News Heater
Zentalis Pharmaceuticals Inc (ZNTL) Stock: A Year of Highs and Lows - The InvestChronicle
Insider Buying: Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Director Acquires 60,000 Shares of Stock - MarketBeat
Zentalis pharmaceuticals director Jan Skvarka buys $103,446 in stock - MSN
Analysts Issue Forecasts for ZNTL Q1 Earnings - Defense World
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Stock Falling -30.99% Over A Month – Any Room For Its Value To Rise? - Marketing Sentinel
Insider Buying: Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Director Purchases $103,200.00 in Stock - Armenian Reporter
Zentalis Pharmaceuticals chief legal officer sells $22,643 in stock - MSN
HC Wainwright Has Bullish Estimate for ZNTL Q1 Earnings - MarketBeat
Zentalis pharmaceuticals officer sells $24,590 in stock - MSN
Zentalis Pharmaceuticals executive sells shares worth $4,475 By Investing.com - Investing.com Australia
FY2024 Earnings Forecast for ZNTL Issued By Leerink Partnrs - MarketBeat
Zentalis Pharmaceuticals Llc Stock: Executives Sell Shares Amid Market Volatility - sharewise
High-Profile Executives Make Bold Moves with Zentalis Pharmaceuticals Stock - TipRanks
Zentalis pharmaceuticals officer sells $24,590 in stock By Investing.com - Investing.com Nigeria
Analysts review Zentalis Pharmaceuticals Inc’s rating - Knox Daily
Zentalis Pharmaceuticals Inc (ZNTL) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
Zentalis pharmaceuticals director Luke Walker buys $24,966 in stock - MSN
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) -2.98% Decline Turns Investors Away - Stocks Register
Millennium Management LLC Acquires Significant Stake in Zentalis Pharmaceuticals Inc - GuruFocus.com
Top Executives Show Strong Confidence in Zentalis Pharmaceuticals with Major Stock Buys - TipRanks
Finanzdaten der Zentalis Pharmaceuticals Inc-Aktie (ZNTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):